Sun Pharma shares fall as Q2 profit plunges 36%, impacting brokerages’ target prices despite their bullish outlook.
stock market
InnoCare Pharma approval: Is it the best investment now?
InnoCare Pharma approval raises questions about future growth and pricing. Is it worth investing now or has the upside already been priced in?